CD274 and non-small cell lung carcinoma: This analysis could serve as an auxiliary biomarker alongside PD-L1 immunohistochemistry for advanced NSCLC, potentially enhancing patient stratification and improving selection of tailored therapy for each patient while optimizing the benefit-cost balance in ICI treatment.